147536-97-8

Bosentan (Benzenesulfonamide) is a sulfonamide-derived, competitive and specific endothelin receptor antagonist with a slightly higher affinity for the endothelin A receptor than endothelin B receptor. Bosentan blocks the action of endothelin 1, an extremely potent endogenous vasoconstrictor and bronchoconstrictor, by binding to endothelin A and endothelin B receptors in the endothelium and vascular smooth muscle. Bosentan decreases both pulmonary and systemic vascular resistance and is particularly used in the treatment of pulmonary arterial hypertension.

Bosentan hydrate (Ro 47-0203) is a competitive and dual antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors.

Benzenesulfonamide (Benzosulfonamide) ia an inhibitor of carbonic anhydrases.

Bosentan-D4 ist against endothelin-1 (ET) by targeting both ET A and ET B receptors. It exhibits binding affinities with K i values of 4.7 nM for ET A and 95 nM for ET B in human SMC.

Bosentan-[13C2,D4] (Standard) is a reference standard of Bosentan-[13C2,D4] intended for quantitative analysis, quality control, and related biochemical research applications.

Orthanilamide (Orthanilamide) is a molecule containing the sulfonamide functional group attached to an aniline.